Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 8.14
-0.31 (-3.67%)
Sep 10, 2026, 1:08 PM HKT
Alphamab Oncology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 518.03 | 566.24 | 640.08 | 218.77 | 166.85 | 146.02 |
| 518.03 | 566.24 | 640.08 | 218.77 | 166.85 | 146.02 | |
Revenue Growth | -34.09% | -11.54% | 192.58% | 31.12% | 14.26% | - |
Cost of Revenue | 58.61 | 63.55 | 60.32 | 55.24 | 44.21 | 3.03 |
Gross Profit | 459.42 | 502.69 | 579.77 | 163.54 | 122.64 | 142.99 |
Selling, General & Admin | 83.7 | 84.18 | 75.11 | 79.56 | 86.94 | 77.55 |
Research & Development | 573.82 | 571.8 | 403.65 | 407.3 | 468.07 | 481.06 |
Operating Expenses | 657.53 | 655.98 | 478.76 | 486.86 | 555.01 | 558.61 |
Operating Income | -198.1 | -153.29 | 101.01 | -323.33 | -432.37 | -415.62 |
Interest Expense | -6.44 | -7.45 | -9.92 | -12.18 | -14.21 | -13.18 |
Interest & Investment Income | 27.69 | 35.3 | 49.26 | 74.04 | 33.87 | 27.81 |
Currency Exchange Gain (Loss) | -9.53 | -5.33 | 13.45 | 33.19 | 66.71 | -41.41 |
Other Non Operating Income (Expenses) | 10.41 | 16.84 | 12.56 | 17.68 | 20.28 | 29.99 |
EBT Excluding Unusual Items | -175.98 | -113.94 | 166.34 | -210.59 | -325.72 | -412.42 |
Pretax Income | -175.98 | -113.94 | 166.34 | -210.59 | -325.72 | -412.42 |
Earnings From Continuing Operations | -175.98 | -113.94 | 166.34 | -210.59 | -325.72 | -412.42 |
Net Income | -175.98 | -113.94 | 166.34 | -210.59 | -325.72 | -412.42 |
Net Income to Common | -175.98 | -113.94 | 166.34 | -210.59 | -325.72 | -412.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 965 | 961 | 962 | 960 | 937 | 935 |
Shares Outstanding (Diluted) | 965 | 961 | 984 | 960 | 937 | 935 |
Shares Change | -3.07% | -2.31% | 2.53% | 2.50% | 0.11% | 0.62% |
EPS (Basic) | -0.18 | -0.12 | 0.17 | -0.22 | -0.35 | -0.44 |
EPS (Diluted) | -0.18 | -0.12 | 0.17 | -0.22 | -0.35 | -0.44 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -153.48 | 190.56 | -239.02 | -429.96 | -478.72 |
Free Cash Flow Per Share | - | -0.16 | 0.19 | -0.25 | -0.46 | -0.51 |
Gross Margin | 88.69% | 88.78% | 90.58% | 74.75% | 73.50% | 97.93% |
Operating Margin | -38.24% | -27.07% | 15.78% | -147.79% | -259.14% | -284.63% |
Profit Margin | -33.97% | -20.12% | 25.99% | -96.26% | -195.22% | -282.44% |
Free Cash Flow Margin | - | -27.11% | 29.77% | -109.26% | -257.70% | -327.84% |
EBITDA | -135.67 | -91.54 | 165.36 | -267.54 | -391.83 | -387.1 |
EBITDA Margin | -26.19% | -16.17% | 25.83% | -122.29% | -234.85% | -265.10% |
D&A For EBITDA | 62.44 | 61.75 | 64.35 | 55.78 | 40.54 | 28.52 |
EBIT | -198.1 | -153.29 | 101.01 | -323.33 | -432.37 | -415.62 |
EBIT Margin | -38.24% | -27.07% | 15.78% | -147.79% | -259.14% | -284.63% |